As a result, the state is looking to eliminate Medicaid coverage of the drugs when prescribed only for obesity, which would leave Medicaid patients who are currently prescribed GLP-1s for weight loss in limbo
Expert Opinions and Consensus In the absence of robust clinical trials, healthcare professionals often turn to expert opinions and consensus guidelines for guidance
3 Ways GLP-1 Drugs Could Impact Your Hospitals Future Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand
Hu P, Li K, Peng XX, Kan Y, Yao TJ, Wang ZY, et al
References National Institutes of Health Office of Dietary Supplements MedlinePlus National Organization for Rare Disorders Mayo Clinic European Food Safety Authority This article is for general information only and is not a substitute for professional medical advice